- Research article
- Open Access
- Open Peer Review
The liver is a common non-exocrine target in primary Sjögren's syndrome: A retrospective review
© Kaplan and Ike; licensee BioMed Central Ltd. 2002
- Received: 16 April 2002
- Accepted: 13 September 2002
- Published: 13 September 2002
The autoimmune destruction of exocrine glands that defines primary Sjögren's syndrome (1°SS) often extends to non-exocrine organs including the liver. We aimed to determine the prevalence of liver disease in patients with 1°SS and to evaluate the association of this complication with other non-exocrine features and serologic markers of autoimmunity and systemic inflammation.
We reviewed 115 charts of patients with 1°SS and further analyzed the 73 cases that fulfilled the European Epidemiology Center Criteria, seeking evidence for clinical and subclinical liver disease.
Liver function tests had been determined in 59 of the 73 patients. Of those, 29 patients (49.1%) had abnormal liver function tests including 20.3% with clinically overt hepatic disease. Liver disease was the most common non-exocrine feature in this cohort. Risk factors for abnormal liver function tests were distributed similarly between the patients with and without liver disease. In 60% of patients with abnormal liver function tests no explanation for this complication was found except for 1°SS. Liver involvement was significantly more common in 1°SS patients who also had evidence of lung, kidney and hematological abnormalities. Patients with abnormal liver function tests were also more likely to have an elevated sedimentation rate and a positive anti-ENA during the course of their disease.
Liver involvement is a common complication in 1°SS. Its presence correlates with systemic disease. We consider that this complication should be routinely sought in patients with 1°SS, especially when a positive anti-ENA or evidence of systemic inflammation is found.
- Liver Disease
- Primary Biliary Cirrhosis
- Autoimmune Hepatitis
- Chronic Active Hepatitis
- Elevated Sedimentation Rate
Primary Sjögren's syndrome (1°SS) is a systemic autoimmune disorder characterized by dry eyes (keratoconjunctivitis sicca), dry mouth (xerostomia) as well as involvement of other exocrine glands. While 1°SS is typically considered an autoimmune exocrinopathy, the immune destruction can often extend to affect non-exocrine organs. Around 25 % of patients with 1°SS can present with involvement of other organs such as the thyroid, central nervous system, lungs, kidney and liver. The association of liver disease and 1°SS was suggested more than 40 years ago . While liver involvement in 1°SS has been considered "rare"  only a few clinical studies specifically address this complication and evaluate the association of liver function tests abnormalities with the severity of 1°SS [3–6].
Liver diseases associated with 1°SS include primary biliary cirrhosis (PBC)-autoimmune cholangitis [8–10], autoimmune hepatitis [5, 6], viral hepatitis (B and C) [11–21], sclerosing cholangitis , and nodular regenerative hyperplasia . In addition, chronic lymphocytic sialadenitis has been found in patients with different types of liver cirrhosis [16–24].
We report the results of a review of cases undertaken to determine the prevalence of abnormal liver function tests (LFTs) and liver disease in patients with 1°SS referred to a tertiary care center and the association of abnormal LFTs with other systemic features and autoimmunity markers of 1°SS.
A total of 115 charts of patients seen at the University of Michigan Medical Center between 1968 and 1996 were reviewed and those that had been coded as Sjögren's syndrome were considered for analysis. Patients were captured from the Rheumatology outpatient clinic, the Rheumatology consults records, different in-patient services and also, through the review of the salivary gland biopsies performed at this institution during those years.
Non-exocrine clinical features considered part of 1°SS for this study (excluding liver)
Lymphocytic interstitial pneumonia, fibrosing alveolitis, pseudolymphoma, lymphoma, pulmonary amyloidosis
Renal tubular acidosis type I, nephrogenic diabetes insipidus, chronic interstitial nephritis, immune-mediated glomerulonephritis
Myocarditis, pericarditis, pericardial effusion, Raynaud's
Atrophic gastritis, pancreatitis
Mononeuritis multiplex, axonal neuropathy, purpura
Coombs positive hemolytic anemia, leukopenia, lymphopenia, thrombocytopenia, hypoplasic bone marrow
Peripheral nervous system
Axonal neuropathy, mononeuritis multiplex
Central nervous system
Aseptic meningitis, cerebral vasculitis, CVA, TIAs, multiple sclerosis "like" changes
Autoimmune thyroid disease
Arthritis, arthralgias, myositis
Laboratory studies reviewed included: a) liver function tests (aspartame amino-transferase (AST), alanine-amino transferase (ALT), alkaline phosphatase (AP), gamma-glutamyl transpeptidase (GGTP), bilirubins, albumin, prothrombin time); b) serological markers of autoimmunity (antinuclear antibodies (ANA), antibodies to extractable nuclear antigens (ENA), rheumatoid factor (RF), anti-dsDNA (anti-double stranded DNA), cryoglobulins, anticardiolipin antibodies (ACL), anti-neutrophil cytoplasmic antibodies (ANCA); c) specific markers of autoimmune liver disease (antimitochondrial (AMA), anti-smooth muscle (ASM) and liver-kidney microsomal antibodies); d) viral hepatitis markers (A, B, C); e) liver imaging studies (abdominal ultrasound, abdominal CT, nuclear medicine studies) ; f) when available, results of liver biopsies.
Subclinical liver disease was considered present when abnormal LFTs (aminotransferases, alkaline phosphatase, GGT or bilirubin) were detected but no clinical signs, symptoms or other laboratory findings of liver dysfunction were found. In addition, we searched for any mention of drug use (immunosuppressive, NSAIDS or others), transfusions, tobacco use and abuse of alcohol or drugs, as well as their association with the onset of abnormal liver function tests.
The statistical analysis included descriptive measures (means, standard deviations and ranges). Comparison of results of patients with and without liver disease was done using t-tests of continuous variables and Fisher's exact test or x2 for categoric measures.
Of the 115 charts reviewed, 73 cases (55 women and 18 men, median age 53) fulfilled EECC for 1°SS and were initially included for analysis. Of the 73 patients, a 54% of them (40 patients) have had a salivary gland biopsy performed. In all these patients, the biopsy confirmed the diagnosis of Sjögren's syndrome. All patients studied had objective evidence of 1°SS, including keratoconjunctivitis sicca, positive labial salivary gland biopsy, autoantibodies and/or salivary gland hypofunction. We excluded those patients without these objective criteria of 1°SS and also those who did not fulfill EECC criteria.
Clinical characteristics of the patients studied
(# of patients) n = 59
FREQUENCY N (%)
* Xerostomia or xerophtalmia
* Abnormal liver function tests
* Physical findings of liver disease
* Other ILD
* CNS vasculitis
* Aseptic meningitis
* MS "like " disease
* Transverse myelitis
* CVAs, TIAs
* Peripheral neuropathy
* Mononeuritis multiplex
* Tubular disorders
* BM hypoplasia
* Hemolytic anemia
* Autoimmune thrombocytopenia
* Prothrombotic states
Arthritis and arthralgias
Autoimmunity markers of the patients studied
FREQUENCY n (%)Total = 59
Mean ± SEM
45 ± 10 mm/hr
1.5 ± 0.6 mg/dl
65 ± 10 IU/ml
12 ± 5 IU/ml
25 ± 3 GPL
For these SS patients studied, abnormal LFTs were more common than any other potential non-exocrine features of SS. Clinical evidence of liver disease, defined in methods section, was found in 12 patients (20.3%), all of whom had abnormal liver function tests. Two deaths occurred in the population studied, both attributed to liver failure. An additional patient required a liver transplant. In all cases, the diagnosis of 1°SS antedated the onset of liver disease or its diagnosis. Markers of viral hepatitis, sought in 39 patients, were found only in 4. Two patients carried the surface antigen of hepatitis B virus and one had antibodies to hepatitis C virus. In a liver biopsy of a patient who lacked serological markers for hepatitis viruses, hepatitis B virus was detected by in situ hybridization.
W/O LIVER DISEASE
55 ± 10 years
53 ± 15 years
Liver biopsies, done in 8 patients, disclosed post-viral chronic active hepatitis (3), cryptogenic cirrhosis (2), and one case each of post-viral cirrhosis, alcoholic hepatitis, and autoimmune hepatitis.
In this group of Sjögren's patients seen at a tertiary care center, abnormal liver function tests were found to be a common non-exocrine feature of 1°SS. The prevalence of this association was found to be higher in our study than in other previous series [2–7]. The true prevalence could be even higher since liver enzyme profiles were not done in all patients. The prevalence suggested in previous reports ranges from 6 to 58 %, but the definition of hepatic disease varies from the unspecific (e.g. hepatomegaly) to well proven cases of liver disease [1–7, 28]. Denko in 1960 reported that 12% of patients with SS had hepatosplenomegaly . Other studies done in the 1960's also confirmed hepatomegaly in 18–20% of patients with SS [30, 31]. In 1970, Whaley reported liver disease in 6% of patients with SS and mentioned an association with anti-mitochondrial antibodies . In 1986, Tsianos and co-workers described 22 SS patients with gastrointestinal complications, called from a large cohort; only two patients had liver disease, each with chronic active hepatitis . Other studies have reported variable prevalence [3, 28] and different histopathological findings in liver biopsies ranging from cholestatic liver damage (stage I primary biliary cirrhosis) to chronic active hepatitis due to hepatitis C virus.
In our study, liver disease was associated with other non-exocrine manifestations of 1°SS, specifically those affecting lung, kidney and blood cells. Those patients with serological evidence of systemic inflammation, as shown by an elevated sedimentation rate, were more likely to have liver test abnormalities. Also, the presence of a positive anti-ENA correlated positively with hepatic disease. An association of ENA response with liver disease has been described in children with autoimmune hepatitis, where anti-ENA-positive patients demonstrated more severe liver test abnormalities than those who were anti-ENA-negative . In another study, a 15 % of patients with various chronic liver diseases were found to be anti-RNP positive .
With etiopathogenesis of 1°SS still an open question , a possible role of hepatitis C virus (HCV) has drawn attention. Recent studies have mentioned HCV incidence in patients with 1SS ranging from 14–19% [11, 12, 16, 18, 21]. Phenotypic characterization of the minor salivary glands with immunohistochemistry in patients with hepatitis C virus infection and/or 1°SS has given conflicting results [14, 15] Some reports mention that the salivary gland findings are strikingly similar in patients with liver disease associated with HCV infection than in those with 1°SS , while others mention distinctive differences between both groups regarding focus score, expression of surface markers in lymphocytes infiltrating the salivary glands and in epithelial cells, as well as differences in the degree of inflammation [14, 15]. Transgenic mice models that carry the HCV envelope genes develop an exocrinopathy affecting salivary and lachrymal glands . Expression of autoimmunity markers also tends to differ between HCV-infection and 1°SS. Positive ENAs are rarely seen in HCV-patients. Also, in most cases sicca symptoms are not present in individuals with HCV as compared with the 1°SS population. Although the prevalence of viral hepatitis markers in our group of patients with liver disease was very low and did not account for most of the cases with abnormal liver function tests, these markers were not sought in a small percentage of these patients. It is important to note that HCV appears to account for a subgroup of patients with exocrine complaints in which half the cases might meet the definition for SS according to European and Manthorpe criteria. However, this subgroup is characterized by the absence of clinical manifestations observed in 1°SS, and the absence of anti-Ro and anti-La .
An aberrant interaction between lymphocytes and different epithelial tissues has been proposed as a mechanism for the damage seen in different organs in 1° SS . Since it has been suggested that the target tissue involved in the autoimmune histopathologic lesions of 1°SS might be the epithelium , it is interesting that the findings in our study point to the association of liver disease with pulmonary and renal abnormalities, all which are characterized by epithelial damage [38, 39]. Epithelial cells have been proposed to be active participants rather than passive targets in the chronic immune response in 1°SS but further studies are needed to establish the role of liver epithelial cells in the pathogenesis of hepatic damage in this disease, including the analysis of HLA expression and cytokine secretion pattern in these cells.
The co-existence of liver disease and the presence of circulating AMAs in Sjögren's patients sera has been pointed as an indicator that liver pathology might be autoimmune and similar to that of primary biliary cirrhosis [4, 7, 8, 10]. In previous studies, a pericholangial lymphocytic infiltration similar to that found in stage I of primary biliary cirrhosis, has been reported in 1°SS with abnormal liver function tests or positivity for AMA [4, 7]. In our review of cases, we found predominance in hepatocellular liver damage rather than cholestatic disease, which would argue against a PBC-type of liver damage. Other authors had proposed that SS associated with PBC should be considered a form of secondary SS that resembles more the "sicca complex" with exocrine features seen in patients with rheumatoid arthritis [40, 41].
Limitations of the study come primarily from being a retrospective analysis. Since the patients were studied in a tertiary care referral center, the severity of the disease and the prevalence of the manifestations might be different from the general 1°SS population. Furthermore, in many cases, Sjögren's syndrome diagnosis had been sought because of otherwise unexplained non-exocrine features. While we could not find an association between use of NSAIDS or other medications and prevalence of liver function tests abnormalities, the study design did not allow us to exclude the possibility of over-the-counter (OTC) medication use that could have affected LFT's measurement. Drug toxicity is certainly an important factor to be considered. However, given that most patients had persistent rather than intermittent abnormalities of LFTs and that the use of hepatotoxic drugs was not elicited in the majority of patients with liver abnormalities, a toxic effect of medications could not be established.
Based on the results of this study, we consider that an evaluation for clinical and serological evidence of liver disease should be done in every patient with 1°SS, particularly if there is evidence of other non-exocrine complications or serological evidence of systemic inflammation. Although no other diagnosis explaining liver disease may be found, the disorders for which treatment might be beneficial (e.g. immunosuppressants for autoimmune hepatitis, interferon-alpha for viral hepatitis, ursodeoxycolic acid for primary biliary cirrhosis) warrant a diligent search in all cases of 1°SS with abnormal liver function.
We thank Mr. Steven Knowlton for his expert secretarial assistance.
- Christianson J: Corneal changes in a case of hepatitis. Acta Ophtalmol. 1954, 32: 161-164.View ArticleGoogle Scholar
- Whaley K, Goudie RB, Williamson J, Nuki G, Dick WC, Buchanan WW: Liver disease in Sjögren's syndrome and rheumatoid arthritis. Lancet. 1970, 1: 861-863. 10.1016/S0140-6736(70)91690-9.View ArticlePubMedGoogle Scholar
- Skopuli FN, Barbatis C, Moutsopoulos HM: Liver involvement in primary Sjogren's syndrome. Br J Rheumatol. 1994, 33: 745-748.View ArticleGoogle Scholar
- Tsianos EB, Vasakos S, Drosos AA, Malamou-Mitsi VD, Moutsopoulos HM HM: The gastrointestinal involvement in primary Sjögren's syndrome. Scand J Rheumatol. 1986, 61: 151-155.Google Scholar
- Lindgren S, Manthorpe R, Eriksson S: Autoimmune liver disease in patients with primary Sjögren's syndrome. J Hepatol. 1994, 20: 354-358.View ArticlePubMedGoogle Scholar
- Masaki N, Hayashi S: Autoimmune liver disease complicating Sjogrens syndrome. Nippon Rinsho. 1995, 53: 2530-2535.PubMedGoogle Scholar
- Webb J, Whaley K, MacSween RN, Nuki G, Dick WC, Buchanan WW: Liver disease in rheumatoid arthritis and Sjögren's syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction. Ann Rheum Dis. 1975, 34: 70-81.View ArticlePubMedPubMed CentralGoogle Scholar
- Hansen BU, Lindgren S, Eriksson S, Henricsson V, Larsson A, Mathorpe R, Warfulnge G: Clinical and immunological features of Sjögren's syndrome in patients with primary biliary cirrhosis with emphasis on focal sialadenitis. Acta Med Scand. 1988, 224: 611-619.View ArticlePubMedGoogle Scholar
- Archimandritis A, Tjivras M, Tsirantonaki M, Hatzis G, Delladetsima I: Sjogren's syndrome with antimitochondrial antibody-negative primary biliary cirrhosis: a case of autoimmune cholangitis. J Clin Gastroenterol. 1995, 20: 268-278.View ArticlePubMedGoogle Scholar
- Alarcon-Segovia D, Diaz-Jouanen E, Fishbein E: Features of Sjogren's syndrome in primary biliary cirrhosis. Ann Intern Med. 1973, 79: 31-38.View ArticlePubMedGoogle Scholar
- Gumber SC, Chopra S: Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med. 1995, 123: 515-520.View ArticleGoogle Scholar
- Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, Mal F, Callard P, Beaugrand M: Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet. 1992, 339: 321-323. 10.1016/0140-6736(92)91645-O.View ArticlePubMedGoogle Scholar
- Pirisi M, Scott C, Fabris C, Ferraccioli G, Soardo G, Ricci R, Toniutto P, Avellini C, Vitulli D, Miotti AM: Mild sialoadenitis: a common finding in patients with hepatitis C virus infection. Scand J Gastroenterol. 1994, 29: 940-942.View ArticlePubMedGoogle Scholar
- Scott CA, Avellini C, Desinan L, Pirisi M, Ferraccioli G, Bardus P, Fabris C, Casatta L, Bartoli E, Beltrami CA: Chronic lymphocytic sialoadenitis in HCV-related chronic liver disease: comparison of Sjogren's syndrome. Histopathology. 1997, 30: 41-48. 10.1046/j.1365-2559.1997.d01-561.x.View ArticlePubMedGoogle Scholar
- Coll J, Gambus G, Corominas J, Tomas S, Esteban JI, Guardia J: Immunohistochemistry of minor salivary gland biopsy specimens from patients with Sjogren's syndrome with and without hepatitis C virus infection. Ann Rheum Dis. 1997, 56: 390-392.View ArticlePubMedPubMed CentralGoogle Scholar
- Jorgensen C, Legouffe MC, Perney P: Sicca syndrome associated with hepatitis C virus infection. Arthritis Rheum. 1996, 39: 1166-1171.View ArticlePubMedGoogle Scholar
- Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, Deforges L, Duvoux C, Zafrani ES, Duval J: Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994, 19: 841-848. 10.1016/0270-9139(94)90281-X.View ArticlePubMedGoogle Scholar
- Wattiaux MJ: Sindrome de Gougerot Sjogren et virus de l'hepatite C: quels liens?. Presse Medicale. 1997, 26: 652-657.Google Scholar
- Koike K, Moriya K, Ishibashi K, Yotsuyagani H, Shintani Y, Fujie H, Kurokawa K, Matsura Y, Miyamura T: Sialadenitis histologically resembling Sjögren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA. 1997, 94: 233-236. 10.1073/pnas.94.1.233.View ArticlePubMedPubMed CentralGoogle Scholar
- Aprosin ZG, Serov VV, Lopatkina TN: The hepatitis B virus as a probable etiological factor in Sjögren's disease. Ter Arkh. 1993, 65: 73-78.PubMedGoogle Scholar
- Garcia Carrasco M, Ramos M, Cervera R, Font J, Vidal J, Munoz FJ, Miret C, Espinosa G, Ingelmo M: Hepatitis C virus infection in primary'Sjögren's syndrome: prevalence and clinical significance in a series of 90 patients. Ann Rheum Dis. 1997, 56: 173-175.View ArticlePubMedPubMed CentralGoogle Scholar
- Montefusco PP, Geiss AC AC, Bronzo RL, Randall S, Kahn E, McKinley MJ: Sclerosing cholangitis, chronic pancreatitis and Sjögren's syndrome: a syndrome complex. Am J Surg. 1984, 147: 822-826. 10.1016/0002-9610(84)90212-5.View ArticlePubMedGoogle Scholar
- Gonzalez-Alvaro I, Carmona-Ortell L, Amigo-Etxenagusia A, Castaneda Sanz S: Nodular regenerative hyperplasia of the liver and primary Sjögren's syndrome. J Rheumatol. 1994, 21: 168-169.PubMedGoogle Scholar
- Oscott CA, Avellini C, Desinan L, Pirisi M, Ferraccioli GF, Bardus P, Fabris C, Casatt L, Bartoli E, Beltrami CA: Chronic lymphocytic sialoadenitis in HCV-related chronic liver disease: comparison of Sjögren's disease. Histopathology. 1987, 30: 41-48. 10.1046/j.1365-2559.1997.d01-561.x.View ArticleGoogle Scholar
- Czaja AJ: The variant forms of autoimmune hepatitis. Ann Intern Med. 1996, 125: 588-598.View ArticlePubMedGoogle Scholar
- Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, Coll I, De Vita S: Preliminary criteria for the classification of Sjögren's syndrome. Arthr Rheum. 1993, 36: 340-347.View ArticleGoogle Scholar
- Vitali C, Bombardieri S: The diagnosis of Sjogren's syndrome: definition and validation of classification criteria for this disorder. Ann Med Interne (Paris). 1998, 149: 12-16.Google Scholar
- Vogel C, Wittenborg A, Reichart P: The involvement of liver in Sjögren's syndrome. J Oral Surg. 1980, 50: 26-31.View ArticleGoogle Scholar
- Denko CW, Bergestal PM: The sicca syndrome (Sjogren's syndrome):. Arch Intern Med. 1960, 105: 849-853.View ArticlePubMedGoogle Scholar
- Vanselow NA, Dodson VN, Angell DE: A clinical study of Sjogren's syndrome. Ann Intern Med. 1963, 58: 124-129.View ArticlePubMedGoogle Scholar
- Bloch KJ, Buchanan WW, Wohl MJ: Sjogren's syndrome. A clinical pathological and serological study of sixty-nine cases:. Medicine (Baltimore). 1965, 44: 187-192.View ArticleGoogle Scholar
- Gregorio GV, Davies ET, Mieli-Vergani G, Vergani D: Significance of extractable nuclear antigens in childhood autoimmune liver disease. Clin Exp Immunol. 1995, 102: 308-313.View ArticlePubMedPubMed CentralGoogle Scholar
- Konikoff F, Shoenfeld Y, Isenberg DA, Barrison I, Sobe T, Theodor E, Slor H: Anti-RNP antibodies in chronic liver disease. Clin Exp Rheumatol. 1987, 5: 359-361.PubMedGoogle Scholar
- Moutsopoulos HM: Immunopathology of Sjogren's syndrome. More questions than answers. Lupus. 1993, 2: 209-211.View ArticlePubMedGoogle Scholar
- Loustaud-Ratti V, Riche A, Liozon E, Labrouse F, Soria P, Rogez S, Babany G, Delaire L, Denis F, Vidal E: Prevalence and characteristics of Sjogren's syndrome or sicca syndrome in chronic hepatitis C virus infection: a prospective study. J Rheumatol. 2001, 28: 2245-2251.PubMedGoogle Scholar
- Fox RI, Kang HI: Pathogenesis of Sjogren's syndrome. Rheum Dis Clin North Am. 1992, 18: 517-538.PubMedGoogle Scholar
- Moutsopoulos HM, Kordossis T: Sjögren's syndrome revisited. Autoimmune epithelitis. Br J Rheumatol. 1935, 3: 204-206.Google Scholar
- Siamopoulos KC, Mavridis AK, Elisaf M, Drosos AA, Moutsopoulos HM: Kidney involvement in primary Sjogren's syndrome. Scand J Rheumatol. 1986, 61: 156-160.Google Scholar
- Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM: Respiratory manifestations in primary Sjogren's syndrome: A clinical, functional and histologic study. Chest. 1985, 88: 226-229.View ArticlePubMedGoogle Scholar
- St Clair EW, Angellilo JC, Singer KH: Expression of cell adhesion molecules in the salivary gland microenvironment of Sjogren's syndrome. Arthr Rheum. 1992, 35: 62-66.View ArticleGoogle Scholar
- Moutsopoulos HM, Chised TM, Mann DL, Klippel JH, Fauci AS, Frank MM, Lawley TJ, Hamburger MJ: Sjogren's syndrome (sicca syndrome). Current Issues. Ann Intern Med. 1980, 92: 212-220.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/2/21/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.